NCT00789633 is a Phase 3 clinical trial of Masitinib in Pancreatic Cancer, sponsored by AB Science.

Who is sponsoring NCT00789633?

NCT00789633 is sponsored by AB Science.

What drugs are being tested in NCT00789633?

Interventions in NCT00789633: Masitinib, Placebo, Gemcitabine.

What condition does NCT00789633 study?

NCT00789633 studies Pancreatic Cancer.

Is NCT00789633 still recruiting?

NCT00789633 is currently completed. Last updated 17 December 2018.

Last reviewed 2018-12-17 · How we verify

NCT00789633

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Completed Phase 3 Last updated 17 December 2018

What this trial tests

Phase 3 trial testing Masitinib in Pancreatic Cancer in 353 participants. Completed in 31 August 2012.

Timeline

25 November 2008

Primary endpoint
23 December 2011

31 August 2012

Quick facts

Lead sponsor	AB Science
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	353
Start date	25 November 2008
Primary completion	23 December 2011
Estimated completion	31 August 2012
Sites	68 locations across France, Romania, Lebanon, United States, Czechia

Drugs / interventions tested

Masitinib — full drug profile →
Placebo
Gemcitabine (gemcitabine) — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

AB Science — full company profile →

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to compare the efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine in patients with advanced/metastatic pancreatic cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Small molecule inhibitors targeting the cancers.
Liu GH, Chen T, Zhang X, Ma XL, et al · · 2022 · cited 127× · PMID 36254250 · DOI 10.1002/mco2.181
Targeting fibroblast growth factor pathways in prostate cancer.
Corn PG, Wang F, McKeehan WL, Navone N. · · 2013 · cited 87× · PMID 24052019 · DOI 10.1158/1078-0432.ccr-13-1550
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Deplanque G, Demarchi M, Hebbar M, Flynn P, et al · · 2015 · cited 77× · PMID 25858497 · DOI 10.1093/annonc/mdv133
Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions.
Strapcova S, Takacova M, Csaderova L, Martinelli P, et al · · 2020 · cited 20× · PMID 32707920 · DOI 10.3390/cancers12082005
Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma.
Rebelo R, Polónia B, Santos LL, Vasconcelos MH, et al · · 2021 · cited 19× · PMID 33804613 · DOI 10.3390/ph14030280
Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma.
Mashayekhi V, Mocellin O, Fens MHAM, Krijger GC, et al · · 2021 · cited 16× · PMID 34522225 · DOI 10.7150/thno.60350
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
Chugh R, Griffith KA, Davis EJ, Thomas DG, et al · · 2015 · cited 16× · PMID 25858498 · DOI 10.1093/annonc/mdv171
The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials.
Siolas D, Morrissey C, Oberstein PE. · · 2020 · cited 7× · PMID 33133736 · DOI 10.1097/jp9.0000000000000052

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other AB Science trials

Trials by the same sponsor.

NCT07174492 — Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients · Phase 3 · not yet recruiting
NCT05449444 — Masitinib for the Treatment of Severe Mast Cell Activation Syndrome · Phase 2 · unknown
NCT05200169 — Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male Subjects · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00789633 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AB Science
Last refreshed: 17 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00789633.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing